Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.
The accumulation of nalidixic acid and 14 fluoroquinolones over a range of external drug concentrations (10-100 mg/L; c. 25-231 microM) into intact cells of Escherichia coli KL-16, Staphylococcus aureus NCTC 8532, Pseudomonas aeruginosa NCTC 10662 and spheroplasts of E. coli was investigated. The effect of 100 microM carbonyl cyanide m-chlorophenyl hydrazone (CCCP) upon the concentration of quinolone accumulated by intact cells and spheroplasts of E. coli was also determined. Except for pefloxacin, there was an increase in the concentration of the six quinolones examined accumulated by E. coli, despite a reduction in fluorescence at alkaline pH. For ciprofloxacin the partition coefficient (P(app)) was constant despite an increase in the pH; however, the P(app) for nalidixic acid decreased significantly with an increase in pH. The concentration of nalidixic acid, ciprofloxacin and enrofloxacin accumulated by E. coli and S. aureus increased with an increase in temperature up to 40 degrees C and 50 degrees C, respectively. Above these temperatures the cell viability decreased. With an increase in drug concentration there was, for intact E. coli and 12/15 agents, and for S. aureus and 10/15 agents, a linear increase in the concentration of drug accumulated. However, for P. aeruginosa and 13/15 agents there was apparent saturation of an accumulation pathway. Assuming 100% accumulation into intact cells of E. coli, for 10/14 fluoroquinolones < or = 40% was accumulated by spheroplasts. CCCP increased the concentration of quinolone accumulated but the increase varied with the agent and the bacterial species. The variation in the effect of CCCP upon accumulation of the different quinolones into E. coli could result from chemical interactions or from different affinities of the proposed efflux transporter for each quinolone. Overall, these data suggest that accumulation of most quinolones into E. coli and S. aureus proceeds by simple diffusion, but that P. aeruginosa behaves differently.
Piddock
L J
LJ
Department of Infection, University of Birmingham, Edgbaston, UK. l.j.v.piddock@bham.ac.uk
Jin
Y F
YF
Ricci
V
V
Asuquo
A E
AE
D000890:Anti-Infective Agents / Q000032:analysis* / Q000493:pharmacokinetics; D002258:Carbonyl Cyanide m-Chlorophenyl Hydrazone / Q000032:analysis / Q000493:pharmacokinetics; D002939:Ciprofloxacin / Q000493:pharmacokinetics; D004058:Diffusion; D004305:Dose-Response Relationship, Drug; D015365:Enoxacin / Q000493:pharmacokinetics; D000077422:Enrofloxacin; D004926:Escherichia coli / Q000737:chemistry*; D005453:Fluorescence; D024841:Fluoroquinolones; D006863:Hydrogen-Ion Concentration; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000032:analysis / Q000493:pharmacokinetics; D011550:Pseudomonas aeruginosa / Q000737:chemistry*; D015363:Quinolones / Q000493:pharmacokinetics; D013104:Spheroplasts / Q000378:metabolism; D013211:Staphylococcus aureus / Q000737:chemistry*; D013696:Temperature
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C070711:MF 961; D015365:Enoxacin; D009268:Nalidixic Acid; D000077422:Enrofloxacin; D002258:Carbonyl Cyanide m-Chlorophenyl Hydrazone; D002939:Ciprofloxacin; C057477:clinafloxacin; C060328:rufloxacin